Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.
Frasci G, Comella P, Carreca I, DeCataldis G, Muci D, Brunetti C, Russo A, Palmeri S, D'Aniello R, Giordano R, D'Aiuto M, Comella G; Southern Italy Cooperative Oncology Group. Frasci G, et al. Among authors: comella p, comella g. Oncology. 2005;68(2-3):223-9. doi: 10.1159/000086778. Epub 2005 Jul 7. Oncology. 2005. PMID: 16015038 Clinical Trial.
Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
Frasci G, Comella P, Thomas R, Di Bonito M, Lapenta L, Capasso I, Botti G, Vallone P, De Rosa V, D'Aiuto G, Comella G. Frasci G, et al. Among authors: comella p, comella g. Cancer Chemother Pharmacol. 2004 Jan;53(1):25-32. doi: 10.1007/s00280-003-0669-x. Epub 2003 Sep 26. Cancer Chemother Pharmacol. 2004. PMID: 14513281 Clinical Trial.
Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
Frasci G, D'Aiuto G, Thomas R, Comella P, Di Bonito M, Lapenta L, D'Aiuto M, Botti G, Vallone P, De Rosa V, D'Aniello R, Giordano R, Comella G. Frasci G, et al. Among authors: comella p, comella g. Oncology. 2005;68(4-6):391-7. doi: 10.1159/000086980. Epub 2005 Jul 12. Oncology. 2005. PMID: 16020968 Clinical Trial.
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials.
Comella P, Gambardella A, Frasci G, Avallone A, Costanzo R; SICOG investigators. Comella P, et al. Crit Rev Oncol Hematol. 2008 Feb;65(2):164-71. doi: 10.1016/j.critrevonc.2007.06.014. Epub 2007 Aug 16. Crit Rev Oncol Hematol. 2008. PMID: 17702595 Clinical Trial.
140 results